Predict your next investment

Venture Capital
embl-ventures.com

See what CB Insights has to offer

Investments

34

Portfolio Exits

6

Funds

2

About EMBL Ventures

EMBL Ventures is an early stage venture capital investor currently managing investments on behalf of major institutional investors in Europe. EMBL Ventures invests in core technologies with global potential and is focused on life-science investments, including therapeutics, target validation and drug design, technology platforms, medical devices and diagnostics.

EMBL Ventures Headquarter Location

107 Boxbergring

Heidelberg, 69126,

Germany

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing EMBL Ventures

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find EMBL Ventures in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest EMBL Ventures News

Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$48 Million) in this Round

Jul 29, 2021

Funds to be used to obtain clinical proof of concept in two programs and to accelerate innovative pipeline focused on restoring immune tolerance to treat and potentially cure autoimmune diseases Initial clinical data for lead program, TPM203, in pemphigus vulgaris expected this year; second program, TPM502, planned to enter clinic by year end for celiac disease In strong support of Topas’ technology and programs, all existing investors – BioMedPartners, Boehringer Ingelheim Venture Fund, EMBL Ventures, Epidarex Capital, Evotec, Gimv and Vesalius Biocapital III – participated in the extension Hamburg, 29 July 2021 — Topas Therapeutics GmbH (Topas), a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of autoimmune diseases, today announced that the Company has successfully extended its Series B round with an additional €18 million (~$22 million) raised, bringing the total for this financing to €40 million. All of Topas’ existing investors participated in the extension. The funding will be used to obtain clinical proof of concept in two programs and to accelerate the Company’s proprietary pipeline based on the Topas Particle Conjugates technology platform. In addition to lead program, TPM203, which is continuing in clinical development for the treatment of pemphigus vulgaris, a second product candidate, TPM502, is now slated to enter the clinic for the treatment of celiac disease by the end of this year. Topas will also be advancing several of its pre-clinical-stage programs, including one for the treatment of rheumatoid arthritis and one for Type I diabetes. Topas’ novel technology induces antigen-specific immune tolerance by harnessing the liver’s natural tolerization capabilities. The Company is utilizing this platform to develop products for autoimmune diseases where better treatment options and cures are urgently needed. Klaus Martin, Ph.D., Chief Executive Officer of Topas, said: “We are excited by the trust our investors are showing by participating in this extended financing round, recognizing our progress and underpinning their great belief in the potential of Topas’ innovative technology and programs. This strong support is enabling us to accelerate our product development work and to advance several programs in parallel. We look forward to seeing the first clinical results from our platform, expected later this year.” Topas has raised a total of €58 million since its inception. The recent Series B extension is enabling the Company to accelerate the development of various autoimmune disease programs. Erich F. Greiner, M.D., Chairman of the Supervisory Board, said: “I am very pleased and grateful that all of Topas’ investors decided to further strengthen the Company and its programs. We are delighted by the progress we have made to date with the Topas nanoparticle conjugate technology platform and eagerly await the first clinical results. Once clinical proof of concept is established, we see multiple opportunities for this unique and versatile platform to rapidly generate additional exciting programs in a variety of disease areas. The Topas technology has the potential to bring truly breakthrough products to patients with diseases of high unmet medical need for which there are currently no effective or curative treatment options.” About Topas Therapeutics Topas Therapeutics GmbH is a clinical-stage, private biotechnology company, which focuses on developing nanoparticle-based therapeutics to address areas of major unmet need, including autoimmune diseases, allergies, and anti-drug immune responses. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s natural tolerization capabilities. The Company has several proprietary programs; lead product candidate, TPM203, is in clinical testing for pemphigus vulgaris, an orphan disease. A second program, TPM 502, is being developed for the treatment of celiac disease and expected to enter the clinic by the end of the year. Topas has several other proprietary programs, including in rheumatoid arthritis and Type I diabetes, in pre-clinical development. Other programs are in the area of anti-drug immune responses, such as in gene therapy and with anti-drug antibodies and are available for partnering. Topas’ investors are: BioMedPartners, Boehringer Ingelheim Venture Fund, EMBL Ventures, Epidarex Capital, Evotec, Gimv and Vesalius Biocapital III. For additional information, please visit http://www.topas-therapeutics.com . Click here for original Press Release. Search for:

EMBL Ventures Investments

34 Investments

EMBL Ventures has made 34 investments. Their latest investment was in Topas Therapeutics as part of their Series B - II on July 7, 2021.

CBI Logo

EMBL Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/29/2021

Series B - II

Topas Therapeutics

$21.39M

No

BioMedPartners, Boehringer Ingelheim Venture Fund, Epidarex Capital, Evotec, Gimv, and Vesalius BioCapital

2

4/30/2018

Series B

Crescendo Biologics

$70M

No

Andera Partners, IP Group, Quan Capital, Sofinnova Partners, and Takeda Ventures

13

4/26/2017

Series D

Arsanis

$45.5M

No

Alexandria Venture Investments, Anna Maria and Stephen Kellen Foundation, Bill & Melinda Gates Foundation, Google Ventures, Neomed Management, OrbiMed Advisors, Polaris Partners, and SV Health Investors

6

1/12/2017

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

6/15/2016

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/29/2021

4/30/2018

4/26/2017

1/12/2017

6/15/2016

Round

Series B - II

Series B

Series D

Series A - II

Series B

Company

Topas Therapeutics

Crescendo Biologics

Arsanis

Subscribe to see more

Subscribe to see more

Amount

$21.39M

$70M

$45.5M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

BioMedPartners, Boehringer Ingelheim Venture Fund, Epidarex Capital, Evotec, Gimv, and Vesalius BioCapital

Andera Partners, IP Group, Quan Capital, Sofinnova Partners, and Takeda Ventures

Alexandria Venture Investments, Anna Maria and Stephen Kellen Foundation, Bill & Melinda Gates Foundation, Google Ventures, Neomed Management, OrbiMed Advisors, Polaris Partners, and SV Health Investors

Sources

2

13

6

10

10

EMBL Ventures Portfolio Exits

6 Portfolio Exits

EMBL Ventures has 6 portfolio exits. Their latest portfolio exit was Immatics Biotechnologies on July 02, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/2/2020

Reverse Merger

$991

3

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

7/2/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

Reverse Merger

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

EMBL Ventures Fund History

2 Fund Histories

EMBL Ventures has 2 funds, including EMBL Technology Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

11/11/2011

EMBL Technology Fund II

Early-Stage Venture Capital

$54.79M

1

2/28/2003

EMBL Technology Fund

Subscribe to see more

$99M

10

Closing Date

11/11/2011

2/28/2003

Fund

EMBL Technology Fund II

EMBL Technology Fund

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Status

Amount

$54.79M

$99M

Sources

1

10

EMBL Ventures Team

3 Team Members

EMBL Ventures has 3 team members, including current Founding Partner, Christof Antz.

Name

Work History

Title

Status

Christof Antz

Founding Partner

Current

Stefan Herr

Founding Partner

Current

Jan Adams

Kauffman Fellows

Managing Director

Former

Name

Christof Antz

Stefan Herr

Jan Adams

Work History

Kauffman Fellows

Title

Founding Partner

Founding Partner

Managing Director

Status

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.